Bristol-Myers Squibb, Otsuka say FDA OKs Abilify for Treatment of 
Irritability Associated with Autistic Disorder in Children
 From M2 Europharma - Nov 23, 2009
US pharmaceutical and nutritional products maker Bristol-Myers Squibb 
Company and Japanese Otsuka Pharmaceutical Co Ltd said on 20 November 
that the FDA has approved the supplemental NDA for Abilify for the 
treatment of irritability associated with autistic disorder in 
pediatric patients ages 6 to 17 years.

www.peoplewho.org